Review of TA174; Rituximab for the first line treatment of chronic lymphocytic leukaemia, TA193; Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia

The Institute was proposing that the both pieces of guidance should be moved to the static list of technology appraisals.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.  TA174 and 193 will therefore be moved to the list of static guidance.  However, if NICE is notified of a significant change to the evidence base at any stage in the future then this could trigger further consideration and another review proposal.

March 2014